Objectives: This review aims to bridge genomic insights with oncology nursing practice, promoting risk-informed care for patients with hereditary breast cancer (HBC).
Methods: This study reviewed publications from 2018 to 2024, searching PubMed, CINAHL, and Cochrane under PRISMA guidelines. It systematically reviews GI, emphasizing sporadic and hereditary breast cancer (BC), including BRCA1/2-related hereditary breast and ovarian cancer syndrome (HBOC), Li-Fraumeni syndrome (TP53 mutations), and Lynch syndrome (MSI-driven BC).
Results: Key genomic alterations such as TP53, BRCA1/2, and BCL2 mutations were found across various BC subtypes, including triple-negative, HER2-positive, and hormone receptor-positive tumors. Given the hereditary nature of some BC cases, genetic testing is crucial for risk assessment and early intervention, particularly as part of personalized screening protocols. Inhibiting these pathways with BCL2 inhibitors, PARP inhibitors for BRCA-mutated tumors, and immune checkpoint inhibitors for MSI-high tumors represents a promising therapeutic strategy.
Conclusions: This review highlights the importance of integrating genomic findings into personalized care planning, genetic counseling, and patient education.
Implications for nursing practice: Oncology nurses play a central role in applying genomic knowledge in patient care. They support informed decision-making regarding genetic testing, encourage adherence to surveillance protocols, monitor patients on targeted therapies, and advocate for equitable access to genetic services.
Objective: To map the professional roles of nurses in genetic counseling (GC) for hereditary neoplastic syndromes (HNS).
Methods: A scoping review was conducted following the JBI methodological framework. The search involved three stages-strategy validation, database querying, and reference tracking-and included SCOPUS, Medline via PubMed, CINAHL, and Web of Science, between March and April 2024.
Results: From 1,089 identified records, 18 studies met the inclusion criteria. Most were conducted in the United States (12/66.6%). The roles of nurses in GC included risk assessment, pre- and post-test counseling, and patient follow-up. Fewer studies reported nurse-led coordination of GC services, reflecting a gap in leadership and institutional autonomy. The scope of practice varied depending on professional training, national regulations, and local protocols.
Conclusion: This scoping review substantiates nurses' central role in GC for HNS. However, their autonomy is constrained by policies and inequities. Enhanced education and standardized nurse-led protocols can strengthen GC, reduce disparities, and expedite prevention.
Implications for nursing practice: To meet the rising demand for oncology genetic services, policymakers should fund nurse education and training, clarify professional roles, and expand nurses' decision-making autonomy in GC. Scaling nurse-led, standardized risk-assessment and screening-particularly in primary care and underserved settings-can accelerate preventive access. Establishing nurse-led regional networks will improve equity, reduce disparities, and align cancer genetics services with local health-system contexts by addressing structural barriers.

